PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

MHRA grants approval for Pfizer’s oral COVID-19 antiviral pill

Pfizer’s Paxlovid has a success rate of nearly 90% as a prophylaxis treatment against severe COVID-19 when administered shortly after the patient has been infected with the virus.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the use of a second oral antiviral pill for COVID-19 to be taken at home.

Pfizer’s Paxlovid can be given to those aged 18 years and older with mild-to-moderate symptoms of COVID-19, who are also at risk of developing severe disease. High-risk categories include those with diabetes, heart disease, obesity, and those over the age of 60.

Paxlovid boasts a nearly 90% success rate in preventing severe illness among those who fall into these categories when taken soon after becoming infected with COVID-19. The agency recommended taking the pill within five days of a patient’s first symptoms.

The pill is to be taken orally twice a day for five days. Paxlovid is a mixture of two active ingredients, PF-07321332 and ritonavir, which acts by hindering a protease needed for the virus to replicate. These inhibitors are similar to those used to treat HIV, making the treatment beneficial for patients with weakened immune systems.

“We now have a further antiviral medicine for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting before COVID-19 has progressed to a severe stage,” shared Dr June Raine, the MHRA’s chief executive. “I hope the announcement gives reassurance to those particularly vulnerable to COVID-19, for whom this treatment has been approved. For these individuals, this treatment could be life-saving.”

In a clinical trial of the approved patient group, a five-day regimen of Paxlovid taken within three days of symptom development reduced the risk of hospitalisation by 89% compared with those given placebo treatments. The number of hospitalisations and deaths were observed to be 0.8% for those patients given Paxlovid, compared to a rate of 7% among the placebo group.

The MHRA has emphasised that Paxlovid is ‘not a substitute for vaccination’.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026